[en] Boron-neutron capture therapy and photon (⁶⁰Co, lineac) therapy were compared in 146 cases of glioma, meningioma, and sarcoma. The former was undergone in 44 cases and the latter in 102 cases. In grade III and IV glioma (glioblastoma) according to WHO classification, photon therapy group survived an average of 12.9 months, and all of the 41 patients died within 3.9 years. In slow neutron capture therapy group, 5 of 18 patients are alive. This group survived an average of more than 17.8 months and the maximal survival length has exceeded 8 years and 6 months. In grade II supratentorial glioma, the photon group survived an average of 37 months, and neutron capture therapy group survived an average of more than 36 months. However, 80% of the former already died and 80% of the latter are alive. In glioma of the pons and the medulla oblongata, all of the 16 patients of the photon group died after survived an average of 8 months, but neutron capture therapy group survived an average of more than 18 months, the maximal survival length being 4 years and 6 months. Although the cases were a few, slow neutron capture therapy gave favorable results in rhabdomyosarcoma and chondrosarcoma. (Ueda, J.)